Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Beam Therapeutics Inc BEAM

Healthcare Biotechnology
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead... see more

Recent & Breaking News (NDAQ:BEAM)

Beam Therapeutics Provides Business and Pipeline Updates and Reports Third Quarter 2021 Financial Results

GlobeNewswire November 8, 2021

Beam Therapeutics Announces Upcoming Preclinical Data Presentations at the American Society of Hematology Annual Meeting

GlobeNewswire November 4, 2021

Beam Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit

GlobeNewswire October 20, 2021

Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs

GlobeNewswire October 19, 2021

Beam Therapeutics Announces Preclinical Data Highlighting Base Editing Approach to Correct a Glycogen Storage Disease Type Ia Disease-Causing Mutation

GlobeNewswire October 19, 2021

Beam Therapeutics to Present Preclinical Data Highlighting Potential of CAR T Multiplex Base Editing Approach Targeting CD5 at 2021 SITC Annual Meeting

GlobeNewswire October 1, 2021

Beam Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference

GlobeNewswire September 28, 2021

Beam Therapeutics Announces Preclinical Data Highlighting Potential of Base Editors to Target Disease Drivers of Chronic Hepatitis B Infection

GlobeNewswire September 27, 2021

Beam Therapeutics Announces Updated Preclinical Data Highlighting Optimized LNP Delivery Approaches for In Vivo Base Editing to the Liver and Other Tissues

GlobeNewswire September 23, 2021

Beam Therapeutics to Participate in the 2021 Wells Fargo Virtual Healthcare Conference

GlobeNewswire September 8, 2021

Beam Therapeutics Announces Closing of Initial Public Offering

Business Wire February 11, 2020

Beam Therapeutics Announces Multiple Scientific Advances in its Base Editing Technology Platforms

Business Wire February 11, 2020

Beam Therapeutics Announces Pricing of Initial Public Offering

Business Wire February 5, 2020